A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Summary
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria * Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. * Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system Exclusion Criteria * Participants have already received certain types of treatment for extensive stage small cell lung cancer * Participants have certain health conditions, like spread of smal…
Interventions
- BiologicalBMS-986489 (BMS-986012+Nivolumab)
Specified dose on specified days
- BiologicalAtezolizumab
Specified dose on specified days
- DrugCarboplatin
Specified dose on specified days
- DrugEtoposide
Specified dose on specified days
Locations (184)
- Southern Cancer Center, PCDaphne, Alabama
- Local Institution - 0283Hot Springs, Arkansas
- Florida Cancer Specialists - SouthFort Myers, Florida
- Mid Florida Hematology and Oncology CenterOrange City, Florida
- Florida Cancer Specialists - NorthSt. Petersburg, Florida
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb HospitalMarietta, Georgia